Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases

• A targeted mass spectrometric assay was developed for identification and quantification of apoE isoforms (apoE2, E3 and E4), and it was utilized for screening of samples from AD patients (. n=. 39) and patients with other neurodegenerative disorders (. n=. 38). The assay showed good linearity with LOQ corresponds to total apoE concentration of 0.8 and 40. ng/mL in CSF and plasma/serum, respectively. We identified apoE phenotypes with 100% accuracy in clinical samples. We found strong association between genotypes of the individuals and their apoE levels in blood; ε4 allele carriers had significantly lower apoE levels in blood than non-carriers. © 2015.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Alzheimer's disease

ApoE

CSF biomarkers

Protein isoforms

SRM

apolipoprotein E

apolipoprotein E2

apolipoprotein E3

apolipoprotein E4

isoprotein

adult

aged

allele

Alzheimer disease

Article

controlled study

degenerative disease

female

genotype

human

human tissue

major clinical study

male

mass spectrometry

measurement accuracy

phenotype

priority journal

protein analysis

protein blood level

protein cerebrospinal fluid level

screening

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)